Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Tops Revenue Estimates Vanda (VNDA) delivered earnings and revenue surprises of 42.86% and 4.28%, respectively, for the quarter ended December 2024. Do the…
Vanda Pharmaceuticals rejects Cycle Pharmas second takeover offer By Reuters Vanda Pharmaceuticals rejects Cycle Pharmas second takeover offer…
Cycle Pharmaceuticals Stands By $488 Million Offer for Vanda Cycle Pharmaceuticals Ltd. is still interested in acquiring Vanda Pharmaceuticals Inc. after one of Vanda’s drugs failed to receive regulatory…
Court advances Vanda Pharmaceuticals patent case By Investing.com Court advances Vanda Pharmaceuticals patent case…
Global Bipolar Disorder Market Size To Exceed USD 6.47 Billion By 2033 | CAGR Of 1.98% The Global Bipolar Disorder Market Size was Valued at USD 5.32 Billion in 2023, the Worldwide Bipolar Disorder Market Size…
U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents By Reuters U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents…
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDA NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDA NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
Dyspepsia Drug Pipeline Insight Report 2024 Featuring Vanda Pharmaceuticals, Dong-A ST, and Dexa Medica Group Dublin, March 04, 2024 (GLOBE NEWSWIRE) -- The "Dyspepsia - Pipeline Insight, 2024" report has been added to…